Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN versus LINCOMYCIN HCL.
CLEOCIN vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic